Phase II clinical trial of kahalalide F (KF) as a second line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Provencio, Mariano
Izquierdo, Angel
Vinolas, Nuria
Paz-Ares, Luis
Feliu, Jaime
Constenla, Manuel
de las Heras, Begona
Erustes, Mercedes
Izquierdo, Miguel A.
Rosell, Rafael
机构：
[1] Clin Univ Puerta Hierro, Madrid, Spain
[2] Hosp Joseph Trueta, Girona, Spain
[3] Hosp Clin Barcelona, Barcelona, Spain
[4] Hosp Univ Doce Octobre, Madrid, Spain
[5] Hosp La Paz, Madrid, Spain
[6] Complejo Hosp Pontevedra, Pontevedra, Spain
[7] PharmaMar Sau, Oncol, Madrid, Spain
[8] Hosp Univ Germans Trias & Pujol, Badalona, Spain
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：225 / 225
页数：1
相关论文
共 50 条
  • [1] Phase II trial of second-line erlotinib and digoxin in patients with non-small cell lung cancer (NSCLC)
    Kayali, F.
    Janjua, M. A.
    Laber, D. A.
    Miller, D. M.
    Day, J. M.
    Kloecker, G. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] A multicenter phase II trial with gemcitabine plus oxaliplatin as second line treatment in patients with advanced non-small cell lung cancer (NSCLC).
    Kouroussis, C
    Syrigos, K
    Potamianou, A
    Ziras, N
    Ziotopoulos, P
    Stergiou, J
    Ginopoulos, P
    Tselepatiotis, E
    Biozionelou, V
    Georgoulias, V
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 681S - 681S
  • [3] Phase II clinical trial of atezolizumab (A) in advanced non-small cell lung cancer (NSCLC) patients (pts) previously treated with PD1-directed therapy
    Bhattacharya, Saveri
    Yun, Cindy
    Schulze, Katja
    Bruno, Tullia C.
    Kurland, Brenda F.
    Socinski, Mark A.
    Villaruz, Liza Cosca
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] Phase I/II study of MKC-1 and pemetrexed (PEM) as second-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Hanna, N. H.
    Estes, D.
    Arnott, J.
    Marcotte, S.
    Hannah, A.
    Sidor, C. F.
    West, H.
    Clamon, G.
    Hoang, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] Phase II Trial of S-1 as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer
    Govindan, Ramaswamy
    Morgensztern, Daniel
    Kommor, Michael D.
    Herbst, Roy S.
    Schaefer, Paul
    Gandhi, Jitendra
    Saito, Kaku
    Zergebel, Christopher
    Schiller, Joan
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (04) : 790 - 795
  • [6] A phase II study of docetaxel (D) and gemcitabine (G) as second-line treatment in patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Agelaki, S
    Papadakis, E
    Tsiafaki, X
    Rapti, A
    Toubis, M
    Bania, E
    Kalbakis, K
    Kouroussis, C
    Androulakis, N
    Georgoulias, V
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S256 - S256
  • [7] Phase ii trial with Docetaxel in patients (PTS) with non small cell lung cancer (NSCLC)
    Latreille, J
    Laberge, F
    Viallet, J
    Maksymiuk, A
    Shepherd, F
    Gelman, K
    Delorme, F
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 1070 - 1070
  • [8] Metformin as a repurposed therapy in advanced non-small cell lung cancer (NSCLC): results of a phase II trial
    Anish B. Parikh
    Peter Kozuch
    Nicholas Rohs
    Daniel J. Becker
    Benjamin P. Levy
    Investigational New Drugs, 2017, 35 : 813 - 819
  • [9] Metformin as a repurposed therapy in advanced non-small cell lung cancer (NSCLC): results of a phase II trial
    Parikh, Anish B.
    Kozuch, Peter
    Rohs, Nicholas
    Becker, Daniel J.
    Levy, Benjamin P.
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (06) : 813 - 819
  • [10] Phase I/II trial of gefitinib and RAD001 (everolimus) in patients (pts) with advanced non-small cell lung cancer (NSCLC).
    Milton, DT
    Kris, MG
    Azzoli, CG
    Gomez, JE
    Heelan, R
    Krug, LM
    Pao, W
    Pizzo, B
    Rizvi, NA
    Miller, VA
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 646S - 646S
12345